BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 1311779)

  • 1. [Discovery and development of the proton pump inhibitor].
    Igata H; Okabe S
    Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Possible mechanisms for (H+ + K+)-ATPase inhibition by proton pump inhibitors, omeprazole, lansoprazole and SCH 28080].
    Nagaya H; Satoh H
    Nihon Rinsho; 1992 Jan; 50(1):26-32. PubMed ID: 1311786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently.
    Tomiyama Y; Morii M; Takeguchi N
    Biochem Pharmacol; 1994 Nov; 48(11):2049-55. PubMed ID: 7802694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
    Lorentzon P; Bayati A; Lee H; Andersson K
    Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
    [No Abstract]   [Full Text] [Related]  

  • 6. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of gastric (H+ + K+)-ATPase by the substituted benzimidazole, picoprazole.
    Wallmark B; Sachs G; Mardh S; Fellenius E
    Biochim Biophys Acta; 1983 Feb; 728(1):31-8. PubMed ID: 6299338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes in the rat stomach after long-term administration of proton pump inhibitors (AG-1749 and E-3810)].
    Kawai T; Ikeda H; Harada Y; Saitou T
    Nihon Rinsho; 1992 Jan; 50(1):188-93. PubMed ID: 1311785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.
    Nagaya H; Inatomi N; Nohara A; Satoh H
    Biochem Pharmacol; 1991 Oct; 42(10):1875-8. PubMed ID: 1660270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
    Nishioka K; Nagao T; Urushidani T
    Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of gastric proton pump inhibitors on gastric secretion and peptic ulcers].
    Okabe S
    Nihon Yakurigaku Zasshi; 1986 Apr; 87(4):351-60. PubMed ID: 2873085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton-pump inhibition for acid-related disease.
    Holt S
    South Med J; 1991 Sep; 84(9):1078-87. PubMed ID: 1653998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
    Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
    J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proton pump inhibitors: their merits and demerits, and perspectives for future investigation].
    Kamada T; Kawano S; Tsuji S
    Nihon Rinsho; 1992 Jan; 50(1):53-9. PubMed ID: 1347330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on (H(+)-K+)-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors.
    Sih JC; Im WB; Robert A; Graber DR; Blakeman DP
    J Med Chem; 1991 Mar; 34(3):1049-62. PubMed ID: 1848293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
    Asaka M; Kato M; Sato Y; Miyazaki T
    Nihon Rinsho; 1992 Jan; 50(1):104-10. PubMed ID: 1347322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.